Seladelpar RESPONSE study now enrolling
The purpose of this study is to test seladelpar to see if it can improve PBC-related laboratory blood results and symptoms of PBC, such as itching. The goal of the study is
Volixibat – Phase 2 itch study now enrolling
Mirum Pharmaceuticals, Phase 2 clinical trial for Volixibat addressing PBC itch is now enrolling in California, Florida and Mississippi. More sites are planned in North America. Learn more.Study shows Seladelpar improves liver bio markers for PBC patients
In an oral presentation at the AASLD Liver Meeting November 2021, titled “Long-Term Safety and Efficacy of Seladelpar in Patients with Primary Biliary Cholangitis”1 Marlyn J. Mayo, MD, Professor and CymaBay – Seladelpar RESPONSE Phase 3 study now enrolling
For more information see clinicaltrials.gov The following summary is provided by CymaBay Therapeutics. RESPONSE (study number CB8025-32048) is a Phase 3 clinical research study being conducted to learn more about
Elafibranor ELATIVE study now enrolling
The Phase 3 study will consist of Elafibranor 80mg for double blind period (52 to 104 weeks). After completion of the double blind period, participants will be offered the opportunity
Zydus -Saroglitazar -FDA fast track designation for PBC
Drug firm Zydus Cadila on Wednesday said it has received Fast Track Designation from the US health regulator for its investigational drug candidate Saroglitazar Mg, indicated for the treatment of
CymaBay -Seladelpar Phase 3 Enhance Study shows positive results
At AASLD 2020 virtual liver conference, Dr. Gideon Hirschfield presented promising Phase 3 results for Seladelpar a treatment for patients with PBC. Positive outcomes included: 78% of those in the
Escient – upcoming clinical trial for PBC itch
There is a new clinical trial aimed at PBC pruritus. While the study is currently in New Zealand and Australia, there are plans to expand the trial to PBC patients